Ratings SD BioSensor, Inc

Equities

A137310

KR7137310009

End-of-day quote Korea S.E. Other stock markets 18:00:00 2024-05-09 EDT			5-day change	1st Jan Change
10,640 ^KRW	+0.95%		+1.43%	-6.99%

2023	SD Biosensor, Inc announced that it has received KRW 226.0893359 billion in funding from BioNote, Inc.	CI
2023	SD Biosensor, Inc announced that it expects to receive KRW 226.0893359 billion in funding from BioNote, Inc.	CI

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
Low profitability weakens the company.
The company is in debt and has limited leeway for investment
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
For the past year, analysts have significantly revised downwards their profit estimates.
The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Sector: Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
SD BIOSENSOR, INC	-6.99%	951M		-
BIOMÉRIEUX	-1.29%	12.64B		B+
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-0.47%	8.46B		B-
DIASORIN S.P.A.	+5.68%	5.66B		B
LANTHEUS HOLDINGS, INC.	+22.61%	5.27B		C
AUTOBIO DIAGNOSTICS CO., LTD.	-2.03%	4.49B		C
10X GENOMICS, INC.	-53.56%	3.11B		D+
ANDON HEALTH CO., LTD.	+19.30%	2.87B	-	-
MYRIAD GENETICS, INC.	+33.07%	2.31B		C
VITROLIFE AB	-8.42%	2.23B		B-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes